Background: Clinical and experimental analyses have identified a central role for
that may affect one or more target organs including gastrointestinal, cutaneous, respiratory and cardiovascular systems. 3, 4 4 and LTE 4 ]), in promoting the clinical manifestations associated with food-triggered anaphylaxis. [5] [6] [7] [8] [9] [10] [11] Recent studies have revealed that the presence of co-or augmentation factors including exercise, alcohol consumption, non-steroidal anti-inflammatory drugs (NSAID) and infection can increase susceptibility to anaphylaxis. 12 Epidemiological studies suggest that cofactors contribute to~1.5%-30% of all anaphylactic reactions in adults. 12 One cofactor that seems to be important in anaphylaxis is infection, as it is reported to be a relevant cofactor in 2.5%-3% of anaphylactic reactions in children and in 1.3%-11% in adults. [12] [13] [14] Indeed, current guidelines for specific immunotherapy (SIT) with pollen or Hymeoptera venoms advise to discontinue SIT in case of infection. 12, 15 The underlying molecular basis of how infection can act as a cofactor and exacerbate anaphylaxis is not well understood. The primary means by which cofactors are thought to alter the likelihood of an anaphylactic reaction following allergen exposure is through modulating allergen bioavailability and the threshold for cellular activation. 12 Infectious agents (eg viruses and bacteria) upon penetration of epithelial surfaces immediately encounter innate immune cells, such as dendritic cells (DCs) and macrophages, through recognition of distinct evolutionarily conserved structures on pathogens, termed pathogen-associated molecular patterns via pattern recognition receptors (PRRs), for example, Toll-like receptors (TLRs). [16] [17] [18] [19] [20] Activation of TLRs on mononuclear cells, including DCs, monocytes and macrophages (MΦs), 21 stimulates a NFjB-responsive pro-inflammatory cytokine (eg IL-1, IL-6, IL-10, Type I interferons and TNF) response. [22] [23] [24] [25] [26] [27] MCs also express a number of different PRRs, including TLRs. 28, 29 TLR ligands can directly activate MCs by stimulating mitogen-activated protein kinases (MAPKs)-NF-jB and phosphatidylinositol-4,5-biphosphate 3-kinase (PI3K)/AKT signalling cascades causing the release of MC mediators. [30] [31] [32] [33] The impact of TLR activation on MC degranulation and effector function is controversial. Evidence suggests that TLR ligands (eg TLR-2) can suppress MC activation and degranulation via modulation of FceRI expression and cellular compartmentalization. [34] [35] [36] Alternatively, prolonged TLR ligand exposure promotes IgE-mediated MC activation 37, 38 stimulating cytokine release without affecting degranulation or synthesis of eicosanoids. 33 In this study, we used a reductionist approach to directly exam- 
| Peritoneal mast cell analyses
Peritoneal wash, lymph node (LN) and MC analyses were performed as previously described. 42 In brief, mice were killed and a hypodermic needle was inserted into the abdominal cavity (18 gauge). Sterile saline + 10% fetal bovine serum (FBS) (10 mL) was injected into the peritoneal cavity, the abdominal region was gently massaged for 
| Bone marrow (BM) mast cell culture
Bone marrow cells were isolated from 6-to 12-week-old C57BL/6 mice and cultured as previously described. 43, 44 Briefly, C57BL/6 mice femurs and tibias were harvested, and marrow was collected and suspended in RPMI complete media consisting of RPMI supplemented with 10% FBS (Atlanta Biologicals, Lawrenceville, GA, USA), penicillin (100 U/mL), streptomycin (100 mg/mL), sodium pyruvate 
| b-Hexosaminidase release assay
Bone marrow-derived mast cell (BMMC) degranulation was measured by b-hexosaminidase release as described previously. were analysed by one-way or two-way ANOVA and Tukey's multiple comparison post-test. *P < .05, **P < .01, ***P < .001
BMMCs were incubated with 0.5 lg/mL anti-TNP-BSA at 37°C, 5% 
| Peritoneal macrophages (MΦs)
Peritoneal wash and macrophage (MΦ) analyses were performed as previously described. 45 Mice were i.p. injected with 1 mL 3.85%
thioglycolate as previously described. 45 Three days after the i.p.
injection, a peritoneal lavage was performed, and cells were cen- FBS complete DMEM, and LPS stimulation analyses and IL-10 analyses of supernatants were performed as described. 45 
| Statistical analysis
Data are expressed as mean AE SD, unless otherwise stated. In experiments comparing multiple experimental groups, statistical differences between groups were analysed using the one-way ANOVA parametric and a Tukey's multiple comparison post-test. In experiments comparing 2 experimental groups, statistical differences between groups were determined using a Student's t test. P < .05 was considered significant, whereas repeated-measures two-way ANOVA was performed for rectal temperature data. All analyses were performed with Prism 6.0 software (GraphPad Software Inc., San Diego, CA, USA). Murine-based evidence suggests that MCs are involved in the LPS-induced shock response. 46 We examined evidence of MC degranulation and observed no significant increase in serum mMCPT-1 within 2 hours of LPS treatment ( Figure 1D ) suggesting no significant mucosal MC activation following LPS exposure.
To test whether LPS pretreatment modified IgE-mediated anaphylactic responses, 24 hours following LPS challenge, mice were i.v. (Figure 2A,B) . Notably, the level of FceRI expression on pMCs was reduced by~40% compared with pMCs from vehicle-treated C57BL6 mice ( Figure 2C ). To determine whether the MC population in LPS-treated mice was responsive to IgE, we examined intracellular 
| LPS attenuation of IgE-mediated anaphylaxis is short term
To determine the kinetics of LPS-induced protection from IgEmediated reactions, C57BL/6 mice were treated with LPS (1 mg/kg) and challenged with anti-IgE between 24 and 72 hours following LPS treatment. We show that LPS-induced protection was diminishing by 48 hours and was lost by 72 hours following LPS challenge ( Figure 5A,B) . Notably, the loss in the protection of IgE-mediated reactions was associated with the return of FceRI expression on pMCs ( Figure 5E -G) and increased MC activation ( Figure 5D ). We concluded that LPS-induced protection from IgE-mediated reactions is short term and associated with decreased FceRI expression levels. Figure S1A ). Stimulation of
F I G U R E 2 LPS decreased surface expression of FceR1 on peritoneal mast cells. (A) Overlay histogram and (B) quantification of MFI of

BMMCs with LPS for 24 hours led to a dose-dependent decrease in
FceRI expression on BMMCs ( Figure S1A-C) . Notably, the reduction in FceRI MFI on BMMCs, while statistically significant, was reduced by~10% and did not inhibit IgE activation of BMMCs ( Figure S1D ).
Collectively, these studies suggest that LPS can directly decrease FceRI expression on MC populations; however, the level of reduction is small and insufficient to prevent IgE-mediated MC activation.
| LPS attenuation of peritoneal Mast cell (pMC)
FceRI expression is in part IL-10-dependent A number of studies have previously examined the effect of LPS on antigen-induced anaphylaxis in mice; however, these studies have primarily focused on IgG-mediated reactions. 68, 69 Systemic antigen challenge in mice can induce anaphylaxis via IgE-and IgG-dependent pathways. 70 Furthermore, at high systemic antigen dose, anaphylaxis is predominantly mediated by the IgG pathway. 6 Thus, the previous studies describing LPS-mediated suppression of systemic antigen- The potential clinical significance of LPS-induced suppression of MC responsiveness to IgE activation relates to the possible utilization of this pathway to prevent the onset of IgE-mediated reactions during allergen exposure. Allergen immunotherapy is a therapeutic approach to desensitize individuals to environmental and food antigens by manipulation of the immune system by administering increasing doses of allergen over time. 71 The administration of increasing doses of specific allergens through a subcutaneous, oral, rectal or sublingual route over a period of weeks to months has been shown to be efficacious and prevent reactions upon accidental exposure. [71] [72] [73] [74] Unfortunately, subjects undergoing allergen immunotherapy such as oral immunotherapy (OIT) to foods experience allergic reactions during desensitization, with approximately 20% having severe reactions requiring injection of epinephrine. 75, 76 however, this was through alteration of the adaptive T cell response and generation of inhibitory IgG. [82] [83] [84] We identify an additional pathway by which LPS can suppress allergic inflammation through downregulation of FceRI on MCs.
In summary, we show that LPS exposure of C57BL/6 WT mice transiently suppressed the development of IgE-MC-mediated anaphylactic reactions and that LPS-induced suppression was associated with decreased MC activation and decreased surface expression of FceRI.
These studies suggest that TLR-4 agonists may be used as an adjunctive therapeutic approach to prevent adverse IgE-mediated reactions alone or in combination with allergen immunotherapy approaches.
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